



HealthLinx Limited

COMPANY ANNOUNCEMENT

TERMINATION OF CONVERTIBLE NOTE FUNDING AGREEMENT WITH LA JOLLA COVE INVESTORS INC

19th March 2013. Melbourne Australia: HealthLinx Limited (ASX:HTX) today announced that it has completed negotiations to terminate its funding agreement with La Jolla Cove Investors Inc. The funding agreement was entered into in December 2011 to provide up to \$9,000,000 over three years via a convertible debenture. A Settlement Agreement and Mutual Release has been executed without penalty.

The termination of this facility has allowed the company to seek alternative funding for its operational activities and the ongoing commercialisation of its OvPlex™ ovarian cancer diagnostic in Asia and Europe.

About HealthLinx Limited (ASX:HTX)

HealthLinx Limited develops multiple biomarker tests to improve the detection and diagnosis of diseases and for monitoring response to treatment. Commercial targets for development are diseases where there is a clear clinical need for better diagnosis and/or prognosis, and include: Ovarian cancer diagnostic (OvPlex™) targeting US\$270m pa market; and prostate cancer targeting US\$350m pa market.

A biomarker is a specific biochemical in the body that changes with disease onset, progression or in response to treatment.

Enquiries

Greg Rice (Chairman, HealthLinx Limited)

+61 3 9208 4200

www.healthlinx.com.au